Enzo Biochem, Inc. EZB.F Stock
Enzo Biochem, Inc. Price Chart
Enzo Biochem, Inc. EZB.F Financial and Trading Overview
Enzo Biochem, Inc. stock price | 1.08 EUR |
Previous Close | 1.77 EUR |
Open | 1.85 EUR |
Bid | 1.85 EUR x 120000 |
Ask | 1.88 EUR x 120000 |
Day's Range | 1.85 - 1.85 EUR |
52 Week Range | 0.94 - 2.66 EUR |
Volume | 500 EUR |
Avg. Volume | 8 EUR |
Market Cap | 92M EUR |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.44 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
EZB.F Valuation Measures
Enterprise Value | 114.71M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1.295641 |
Price/Book (mrq) | 4.855643 |
Enterprise Value/Revenue | 1.615 |
Enterprise Value/EBITDA | -2.441 |
Trading Information
Enzo Biochem, Inc. Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -11.92% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.66 EUR |
52 Week Low | 0.94 EUR |
50-Day Moving Average | 2.18 EUR |
200-Day Moving Average | 1.84 EUR |
EZB.F Share Statistics
Avg. Volume (3 month) | 8 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 49.73M |
Float | 30.79M |
Short Ratio | N/A |
% Held by Insiders | 21.74% |
% Held by Institutions | 40.87% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | July 31, 2022 |
Most Recent Quarter (mrq) | April 30, 2023 |
Next Fiscal Year End | July 31, 2023 |
Profitability
Profit Margin | -64.18% |
Operating Margin (ttm) | -70.069% |
Gross Margin | 15.26% |
EBITDA Margin | -66.17% |
Management Effectiveness
Return on Assets (ttm) | -35.34% |
Return on Equity (ttm) | -112.37% |
Income Statement
Revenue (ttm) | 71.01M EUR |
Revenue Per Share (ttm) | 1.45 EUR |
Quarterly Revenue Growth (yoy) | -38.60% |
Gross Profit (ttm) | 41.97M EUR |
EBITDA | -46988000 EUR |
Net Income Avi to Common (ttm) | -45575000 EUR |
Diluted EPS (ttm) | -0.65 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.63M EUR |
Total Cash Per Share (mrq) | 0.05 EUR |
Total Debt (mrq) | 21.86M EUR |
Total Debt/Equity (mrq) | 115.5 EUR |
Current Ratio (mrq) | 0.759 |
Book Value Per Share (mrq) | 0.381 |
Cash Flow Statement
Operating Cash Flow (ttm) | -29015000 EUR |
Levered Free Cash Flow (ttm) | -18183876 EUR |
Profile of Enzo Biochem, Inc.
Country | Germany |
State | NY |
City | Farmingdale |
Address | 81 Executive Blvd. |
ZIP | 11735 |
Phone | 212 583 0100 |
Website | https://www.enzo.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 465 |
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in Farmingdale, New York.
Q&A For Enzo Biochem, Inc. Stock
What is a current EZB.F stock price?
Enzo Biochem, Inc. EZB.F stock price today per share is 1.08 EUR.
How to purchase Enzo Biochem, Inc. stock?
You can buy EZB.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Enzo Biochem, Inc.?
The stock symbol or ticker of Enzo Biochem, Inc. is EZB.F.
Which industry does the Enzo Biochem, Inc. company belong to?
The Enzo Biochem, Inc. industry is Diagnostics & Research.
How many shares does Enzo Biochem, Inc. have in circulation?
The max supply of Enzo Biochem, Inc. shares is 51.74M.
What is Enzo Biochem, Inc. Price to Earnings Ratio (PE Ratio)?
Enzo Biochem, Inc. PE Ratio is now.
What was Enzo Biochem, Inc. earnings per share over the trailing 12 months (TTM)?
Enzo Biochem, Inc. EPS is -0.44 EUR over the trailing 12 months.
Which sector does the Enzo Biochem, Inc. company belong to?
The Enzo Biochem, Inc. sector is Healthcare.